381 related articles for article (PubMed ID: 31642931)
1. Assessment of Diagnostic Outcomes of RNA Genetic Testing for Hereditary Cancer.
Karam R; Conner B; LaDuca H; McGoldrick K; Krempely K; Richardson ME; Zimmermann H; Gutierrez S; Reineke P; Hoang L; Allen K; Yussuf A; Farber-Katz S; Rana HQ; Culver S; Lee J; Nashed S; Toppmeyer D; Collins D; Haynes G; Pesaran T; Dolinsky JS; Tippin Davis B; Elliott A; Chao E
JAMA Netw Open; 2019 Oct; 2(10):e1913900. PubMed ID: 31642931
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic Outcomes of Concurrent DNA and RNA Sequencing in Individuals Undergoing Hereditary Cancer Testing.
Horton C; Hoang L; Zimmermann H; Young C; Grzybowski J; Durda K; Vuong H; Burks D; Cass A; LaDuca H; Richardson ME; Harrison S; Chao EC; Karam R
JAMA Oncol; 2024 Feb; 10(2):212-219. PubMed ID: 37924330
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing.
Mersch J; Brown N; Pirzadeh-Miller S; Mundt E; Cox HC; Brown K; Aston M; Esterling L; Manley S; Ross T
JAMA; 2018 Sep; 320(12):1266-1274. PubMed ID: 30264118
[TBL] [Abstract][Full Text] [Related]
4. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
5. Impact of Variant Reclassification in Cancer Predisposition Genes on Clinical Care.
Chiang J; Chia TH; Yuen J; Shaw T; Li ST; Binte Ishak ND; Chew EL; Chong ST; Chan SH; Ngeow J
JCO Precis Oncol; 2021 Nov; 5():577-584. PubMed ID: 34994607
[TBL] [Abstract][Full Text] [Related]
6. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
Tsaousis GN; Papadopoulou E; Apessos A; Agiannitopoulos K; Pepe G; Kampouri S; Diamantopoulos N; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Xanthakis I; Xepapadakis G; Banu E; Eniu DT; Negru S; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
BMC Cancer; 2019 Jun; 19(1):535. PubMed ID: 31159747
[TBL] [Abstract][Full Text] [Related]
7. Rates and Classification of Variants of Uncertain Significance in Hereditary Disease Genetic Testing.
Chen E; Facio FM; Aradhya KW; Rojahn S; Hatchell KE; Aguilar S; Ouyang K; Saitta S; Hanson-Kwan AK; Capurro NN; Takamine E; Jamuar SS; McKnight D; Johnson B; Aradhya S
JAMA Netw Open; 2023 Oct; 6(10):e2339571. PubMed ID: 37878314
[TBL] [Abstract][Full Text] [Related]
8. Observed frequency and challenges of variant reclassification in a hereditary cancer clinic.
Macklin S; Durand N; Atwal P; Hines S
Genet Med; 2018 Mar; 20(3):346-350. PubMed ID: 29215655
[TBL] [Abstract][Full Text] [Related]
9. Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
Chang J; Seng S; Yoo J; Equivel P; Lum SS
Ann Surg Oncol; 2019 Oct; 26(10):3389-3396. PubMed ID: 31342386
[TBL] [Abstract][Full Text] [Related]
10. Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer.
Whitworth PW; Beitsch PD; Patel R; Rosen B; Compagnoni G; Baron PL; Simmons R; Brown EA; Gold L; Holmes D; Smith LA; Kinney M; Grady I; Clark P; Barbosa K; Lyons S; Riley L; Coomer C; Curcio L; Ruiz A; Khan S; MacDonald H; Hughes K; Hardwick MK; Heald B; Munro SB; Nielsen SM; Esplin ED
JAMA Netw Open; 2022 Sep; 5(9):e2232787. PubMed ID: 36136330
[TBL] [Abstract][Full Text] [Related]
11. A multicenter study of clinical impact of variant of uncertain significance reclassification in breast, ovarian and colorectal cancer susceptibility genes.
Makhnoon S; Levin B; Ensinger M; Mattie K; Volk RJ; Zhao Z; Mendoza T; Shete S; Samiian L; Grana G; Grainger A; Arun B; Shirts BH; Peterson SK
Cancer Med; 2023 Feb; 12(3):2875-2884. PubMed ID: 36426404
[TBL] [Abstract][Full Text] [Related]
12. Multi-gene panel testing for hereditary cancer susceptibility in a rural Familial Cancer Program.
Hermel DJ; McKinnon WC; Wood ME; Greenblatt MS
Fam Cancer; 2017 Jan; 16(1):159-166. PubMed ID: 27401692
[TBL] [Abstract][Full Text] [Related]
13. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.
Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S
Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754
[TBL] [Abstract][Full Text] [Related]
14. Characterization of variant reclassification and patient re-contact in a cancer genetics clinic.
Muir SM; Reagle R
J Genet Couns; 2022 Dec; 31(6):1261-1272. PubMed ID: 35763673
[TBL] [Abstract][Full Text] [Related]
15. A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients.
Lincoln SE; Kobayashi Y; Anderson MJ; Yang S; Desmond AJ; Mills MA; Nilsen GB; Jacobs KB; Monzon FA; Kurian AW; Ford JM; Ellisen LW
J Mol Diagn; 2015 Sep; 17(5):533-44. PubMed ID: 26207792
[TBL] [Abstract][Full Text] [Related]
16. Clinical Utility of Functional RNA Analysis for the Reclassification of Splicing Gene Variants in Hereditary Cancer.
Agiannitopoulos K; Pepe G; Papadopoulou E; Tsaousis GN; Kampouri S; Maravelaki S; Fassas A; Christodoulou C; Iosifidou R; Karageorgopoulou S; Markopoulos C; Natsiopoulos I; Papazisis K; Vasilaki-Antonatou M; Venizelos V; Ozmen V; Tansan S; Kaban K; Eniu DT; Chiorean A; Nasioulas G
Cancer Genomics Proteomics; 2021; 18(3):285-294. PubMed ID: 33893081
[TBL] [Abstract][Full Text] [Related]
17. Clinical Utility of Reinterpreting Previously Reported Genomic Epilepsy Test Results for Pediatric Patients.
SoRelle JA; Thodeson DM; Arnold S; Gotway G; Park JY
JAMA Pediatr; 2019 Jan; 173(1):e182302. PubMed ID: 30398534
[TBL] [Abstract][Full Text] [Related]
18. Spectrum of splicing variants in disease genes and the ability of RNA analysis to reduce uncertainty in clinical interpretation.
Truty R; Ouyang K; Rojahn S; Garcia S; Colavin A; Hamlington B; Freivogel M; Nussbaum RL; Nykamp K; Aradhya S
Am J Hum Genet; 2021 Apr; 108(4):696-708. PubMed ID: 33743207
[TBL] [Abstract][Full Text] [Related]
19. Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.
Seifert BA; O'Daniel JM; Amin K; Marchuk DS; Patel NM; Parker JS; Hoyle AP; Mose LE; Marron A; Hayward MC; Bizon C; Wilhelmsen KC; Evans JP; Earp HS; Sharpless NE; Hayes DN; Berg JS
Clin Cancer Res; 2016 Aug; 22(16):4087-4094. PubMed ID: 27083775
[TBL] [Abstract][Full Text] [Related]
20. The impact of variant classification on the clinical management of hereditary cancer syndromes.
Turner SA; Rao SK; Morgan RH; Vnencak-Jones CL; Wiesner GL
Genet Med; 2019 Feb; 21(2):426-430. PubMed ID: 29875428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
